Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
ConditionSubdural Hematoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Manitoba
About this trial
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH.
Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
Eligibility criteria
Qualifiers
None
Disqualifiers
If informed consent cannot be obtained from the patient or their substitute decision maker.
Known allergy to liquid embolic agent
Trial design
Treatments tested in this trial
- Embolization of the middle meningeal artery
Treatment groups
1,000 Participants
are divided into 1 treatment groupLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Health Sciences centreRecruitingR3A 1R9, Winnipeg MB, Manitoba
Canada
CanadaSponsors and collaborators
Source ClinicalTrials.gov